SecBot SecBot

CPRX drug pipeline

Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
3
1 bearish · 2 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercialized (US launch March 2024)

AGAMREE vamorolone Updated Jun 30

What to watch

For a non-medical investor, AGAMREE is a commercial-stage asset already contributing meaningful revenue growth ($117M in 2025, guiding $140-150M for 2026). There's no binary FDA catalyst ahead, so the stock moves on quarterly sales execution and overall company performance. Watch quarterly AGAMREE revenue growth rates and any news about label expansion studies (DMD is the only approved indication). Multiple analysts downgraded CPRX to Hold/Neutral recently, suggesting the easy money from the approval catalyst is behind it.

Bull case
  • AGAMREE revenue grew 154% YoY in 2025 to $117.1M, and 2026 guidance of $140-150M implies another ~20-28% growth, strong commercial momentum for a recently launched drug.
  • Differentiated safety profile (better growth, bone health vs traditional corticosteroids) creates a compelling value proposition that could drive continued share gains in the DMD corticosteroid market.
  • Catalyst holds the license for additional potential indications beyond DMD, which could expand the addressable market. The company has $709M cash and no debt, providing ample resources for lifecycle management.
Bear case
  • Already approved, the defining binary catalyst (FDA approval) has passed. Without a pending regulatory decision or pivotal readout, the stock lacks a near-term binary event to drive outsized gains from this asset.
  • Competes against cheap generic corticosteroids (prednisone) and Emflaza (deflazacort), which have decades of real-world use. Payers may resist switching to a higher-cost branded option.
  • Catalyst withdrew 2026 financial guidance and canceled its Q1 2026 earnings call in May 2026, a bearish signal that created uncertainty about the company's outlook and led to multiple analyst downgrades.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercialized (FDA approval December 2018)

FIRDAPSE amifampridine phosphate Updated Jun 30

What to watch

FIRDAPSE is a cash-generating approved product with patent protection into 2035, but CPRX stock is now primarily an acquisition-arbitrage vehicle: trading at ~$29.27 vs the $31.50 all-cash buyout by Angelini Pharma expected to close Q3 2026. The spread reflects deal-closing risk. There's no drug-specific binary catalyst; the thesis is purely M&A-driven from here.

Bull case
  • FIRDAPSE is the only FDA-approved, evidence-based treatment for LEMS, giving it a de facto monopoly in a defined rare-disease population with high patient need.
  • Product revenue continues to grow strongly: ~$358M in 2025 (17% YoY), with 2026 guidance of $435-450M (21-26% growth) driven by life-cycle management in Idiopathic and Cancer-Associated LEMS.
  • Patent protection extends to at least February 2035 via settlement agreements with Teva, Lupin, and Inventia, securing long-term market exclusivity.
Bear case
  • The stock is now an acquisition-arbitrage position trading at a spread to the $31.50 buyout price, meaning there's limited upside and residual deal-closing risk (regulatory, shareholder, financing).
  • Jacobus Pharmaceuticals' Ruzurgi (amifampridine base) is approved for pediatric LEMS and prescribed off-label in adults, providing a lower-cost competitive alternative to FIRDAPSE.
  • FYCOMPA (perampanel), another Catalyst product, faces generic competition, which could pressure the company's overall financial profile during the deal process.
▼ bearish
Impact
PhaseApproved
Time to marketAlready marketed (approved by FDA in 2012)

FYCOMPA perampanel Updated Jun 30

What to watch

FYCOMPA is a fading revenue contributor for Catalyst, falling from $137M (2024) to a projected $40-45M (2026) as generics have entered. With active promotion discontinued, the drug is essentially being harvested for residual cash flow. The stock is trading near the $31.50 acquisition price, the spread reflects the risk the Angelini deal fails to close, not any FYCOMPA-specific dynamic.

Bull case
  • FYCOMPA still generates meaningful cash flow ($40-45M guided for 2026) with zero promotion cost, effectively free cash flow from a legacy prescription base.
  • The drug treats serious epilepsy conditions (partial-onset seizures and tonic-clonic seizures) with no perfect substitute for all patients, so some residual demand persists even with generics.
  • For acquirer Angelini Pharma, FYCOMPA adds a CNS/epilepsy product to its brain health portfolio with established U.S. commercial infrastructure, it's a bolt-on, not a core value driver.
Bear case
  • Generic competition from Teva (approved May 2025), MSN (approved July 2025), and others has destroyed pricing power, FYCOMPA revenue is projected to collapse ~70% from $137M (2024) to $40-45M (2026).
  • Catalyst has discontinued active promotion of FYCOMPA, confirming management sees no path to defending the franchise against generics.
  • FYCOMPA carries a boxed FDA warning for serious psychiatric and behavioral adverse reactions (aggression, hostility), and is a Schedule III controlled substance, limiting prescriber appetite.